Reported Tuberculosis in the United States, 2021

Return to Main Menu

Table 17. Tuberculosis Cases and Percentages Among Non-U.S.–Born Persons1 by Drug Resistance and History of Previous TB Disease: United States, 1993–2021

See Surveillance Slides #48.

Tuberculosis cases and percentages by drug resistance and history of tuberculosis among non-U.S.–born persons.
Year Total cases2 Isoniazid (INH)-resistant3 Multidrug resistant (MDR)4 Previous TB No previous TB
Total cases INH-resistant MDR Total cases INH-resistant MDR
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
2021 4,408 443 (10.0) 66 (1.5) 176 30 (17.0) 10 (5.7) 4,166 407 (9.8) 56 (1.3)
2020 4,086 388 (9.5) 55 (1.3) 174 28 (16.1) 10 (5.7) 3,875 356 (9.2) 45 (1.2)
2019 5,005 536 (10.7) 80 (1.6) 213 33 (15.5) 14 (6.6) 4,757 498 (10.5) 66 (1.4)
2018 4,952 529 (10.7) 91 (1.8) 235 46 (19.6) 17 (7.2) 4,682 480 (10.3) 73 (1.6)
2017 4,981 526 (10.6) 110 (2.2) 221 52 (23.5) 25 (11.3) 4,736 470 (9.9) 84 (1.8)
2016 4,899 521 (10.6) 89 (1.8) 219 50 (22.8) 18 (8.2) 4,662 468 (10.0) 70 (1.5)
2015 5,002 526 (10.5) 75 (1.5) 218 44 (20.2) 13 (6.0) 4,763 482 (10.1) 62 (1.3)
2014 4,829 521 (10.8) 84 (1.7) 242 58 (24.0) 24 (9.9) 4,558 459 (10.1) 60 (1.3)
2013 4,807 533 (11.1) 87 (1.8) 202 40 (19.8) 10 (5.0) 4,573 491 (10.7) 76 (1.7)
2012 4,820 532 (11.0) 76 (1.6) 229 47 (20.5) 12 (5.2) 4,563 485 (10.6) 64 (1.4)
2011 5,076 571 (11.2) 110 (2.2) 208 50 (24.0) 26 (12.5) 4,844 515 (10.6) 84 (1.7)
2010 5,143 512 (10.0) 89 (1.7) 229 50 (21.8) 14 (6.1) 4,859 457 (9.4) 73 (1.5)
2009 5,419 560 (10.3) 102 (1.9) 226 46 (20.4) 18 (8.0) 5,126 507 (9.9) 83 (1.6)
2008 6,014 635 (10.6) 83 (1.4) 262 44 (16.8) 16 (6.1) 5,653 585 (10.3) 67 (1.2)
2007 6,120 615 (10.0) 102 (1.7) 288 57 (19.8) 16 (5.6) 5,766 549 (9.5) 83 (1.4)
2006 6,110 659 (10.8) 104 (1.7) 289 57 (19.7) 19 (6.6) 5,774 597 (10.3) 84 (1.5)
2005 5,962 625 (10.5) 101 (1.7) 267 52 (19.5) 21 (7.9) 5,653 567 (10.0) 77 (1.4)
2004 6,115 643 (10.5) 98 (1.6) 264 49 (18.6) 23 (8.7) 5,796 588 (10.1) 74 (1.3)
2003 6,204 669 (10.8) 92 (1.5) 271 49 (18.1) 19 (7.0) 5,882 607 (10.3) 70 (1.2)
2002 6,069 683 (11.3) 120 (2.0) 265 57 (21.5) 23 (8.7) 5,731 622 (10.9) 97 (1.7)
2001 6,288 625 (9.9) 110 (1.7) 302 59 (19.5) 26 (8.6) 5,918 559 (9.4) 81 (1.4)
2000 5,976 684 (11.4) 104 (1.7) 272 62 (22.8) 24 (8.8) 5,668 617 (10.9) 80 (1.4)
1999 5,946 677 (11.4) 111 (1.9) 284 55 (19.4) 22 (7.7) 5,600 614 (11.0) 88 (1.6)
1998 6,004 711 (11.8) 93 (1.5) 262 60 (22.9) 17 (6.5) 5,698 644 (11.3) 76 (1.3)
1997 6,036 719 (11.9) 111 (1.8) 286 74 (25.9) 32 (11.2) 5,710 640 (11.2) 79 (1.4)
1996 6,026 717 (11.9) 124 (2.1) 304 74 (24.3) 22 (7.2) 5,684 637 (11.2) 102 (1.8)
1995 6,066 714 (11.8) 128 (2.1) 364 91 (25.0) 42 (11.5) 5,661 619 (10.9) 85 (1.5)
1994 5,685 732 (12.9) 149 (2.6) 338 93 (27.5) 38 (11.2) 5,297 634 (12.0) 110 (2.1)
1993 5,016 643 (12.8) 149 (3.0) 301 75 (24.9) 46 (15.3) 4,674 565 (12.1) 103 (2.2)

1Persons born in the United States, certain U.S. territories, or elsewhere to at least one U.S. citizen parent are categorized as U.S.-born. All other persons are categorized as non-U.S.–born.
2Persons with isolates tested with at least isoniazid and rifiampin.
3Resistance to at least isoniazid.
4Resistance to at least isoniazid and rifampin.

Note: Data for all years are updated through July 8, 2022.